ReviewCancers2022

Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?

Satoshi Ikeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.